IP Library Granted Patent US 9,080,145
Granted Patent B2
US 9,080,145 · App. 12/164,795 · Granted Jul 14, 2015

Single pluripotent stem cell culture

Inventor: Shelley Nelson (Skillman, NJ)
Assignee: LifeScan Corporation
C12N5/0068C12N5/0606C12N5/0608C12N2501/115C12N2501/119C12N2501/16C12N2501/385C12N2501/41C12N2501/415C12N2501/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,080,145
App. No.
12/164,795
Granted
Jul 14, 2015
Kind
B2
Abstract

The present invention relates to the field of pluripotent stem cell culture and methods facilitate pluripotent stem cell culture at industrial levels.

Claims (59)

1. A method for maintaining pluripotent stem cells, comprising the steps of:

a) obtaining clusters of pluripotent stem cells;

b) culturing the cluster of pluripotent stem cells in MEF-conditioned media;

c) releasing the pluripotent stem cells as single cells with an enzyme; and

d) plating the single pluripotent stem cells on a tissue culture substrate comprising an extracellular matrix, and either bFGF or fibroblast conditioned media;

wherein the enzyme: (1) is TrypLE Select™ or TrypLE Express™; (2) is present in a concentration from about 0.5 g/l to about 2.5 g/l;

wherein the enzyme is used to culture the cells for two minutes; and

wherein there is no gain of chromosome abnormalities after releasing the cells.

2. The method of claim 1 , wherein the pluripotent stem cells are released as single cells by treatment with the enzyme at a concentration of about 2.5 g/l.

3. The method of claim 1 , wherein the pluripotent stem cells released as single cells are subsequently cultured with MEF-conditioned media.

4. The method of claim 1 , wherein the tissue culture substrate is selected from the group consisting of matrigel, growth factor-reduced matrigel, fibronectin, laminin, human serum and collagen.

5. The method of claim 4 , wherein the tissue culture substrate is growth factor-reduced matrigel.

6. The method of claim 5 , wherein the growth factor-reduced matrigel is used at a dilution from about 1:30 to about 1:10.

7. The method of claim 6 , wherein the growth factor-reduced matrigel is used at a dilution of 1:30.

8. The method of claim 1 , wherein the pluripotent stem cells are embryonic stem cells.

9. The method of claim 8 , wherein the embryonic stem cells are human.

10. A method for passaging pluripotent stem cells, comprising the steps of:

a) obtaining clusters of pluripotent stem cells;

b) culturing the cluster of pluripotent stem cells in MEF-conditioned media;

c) releasing the pluripotent stem cells as single cells with an enzyme;

d) plating the single pluripotent stem cells on a tissue culture substrate;

e) allowing the single pluripotent stem cells to expand;

f) releasing the single pluripotent stem cells; and

g) plating the single pluripotent stem cells on a new tissue culture substrate comprising an extracellular matrix, and either bFGF or fibroblast conditioned media;

wherein the enzyme: (1) is TrypLE Select™ or TrypLE Express™; (2) is present in a concentration from about 0.5 g/l to about 2.5 g/l;

wherein the enzyme is used to culture the cells for two minutes; and

wherein there is no gain of chromosome abnormalities after releasing the cells.

11. The method of claim 10 , wherein the pluripotent stem cells are released as single cells by treatment with the enzyme at a concentration of 2.5 g/l.

12. The method of claim 10 , wherein the pluripotent stem cells released as single cells are subsequently cultured in MEF-conditioned media.

13. The method of claim 10 , wherein the tissue culture substrate is selected from the group consisting of matrigel, growth factor-reduced matrigel, fibronectin, laminin, human serum and collagen.

14. The method of claim 13 , wherein the tissue culture substrate is growth factor-reduced matrigel.

15. The method of claim 14 , wherein the growth factor-reduced matrigel is used at a dilution from about 1:30 to about 1:10.

16. The method of claim 15 , wherein the growth factor-reduced matrigel is used at a dilution of 1:30.

17. The method of claim 10 , wherein the pluripotent stem cells are embryonic stem cells.

18. The method of claim 17 , wherein the embryonic stem cells are human.

19. The method of claim 10 , wherein the single pluripotent stem cells on a new tissue culture substrate are passaged onto another tissue culture substrate by releasing the cells and plating the released cells onto another tissue culture substrate.

20. A method for maintaining pluripotent stem cells, comprising the steps of:

a) obtaining clusters of pluripotent stem cells;

b) culturing the cluster of pluripotent stem cells in MEF conditioned media;

c) releasing the pluripotent stem cells as single cells with an enzyme; and

d) plating the single pluripotent stem cells on a tissue culture substrate comprising an extracellular matrix, and MEF-conditioned media;

wherein the enzyme: (1) is TrypLE Select™ or TrypLE Express™; (2) is present in a concentration from about 0.5 g/l to about 2.5 g/l;

wherein the enzyme is used to culture the cells from two to five minutes; and

wherein there is no gain of chromosome abnormalities after releasing the cells.

21. A method for passaging pluripotent stem cells, comprising the steps of:

a) obtaining clusters of pluripotent stem cells;

b) culturing the cluster of pluripotent stem cells in MEF conditioned media;

c) releasing the pluripotent stem cells as single cells with an enzyme; and

d) plating the single pluripotent stem cells on a tissue culture substrate;

e) allowing the single pluripotent stem cells to expand;

f) releasing the single pluripotent stem cells; and

g) plating the single pluripotent stem cells on a new tissue culture substrate comprising an extracellular matrix, and MEF-conditioned media;

wherein the enzyme: (1) is TrypLE Select™ or TrypLE Express™; (2) is present in a concentration from about 0.5 g/l to about 2.5 g/l;

wherein the enzyme is used to culture the cells from two to five minutes; and

wherein there is no gain of chromosome abnormalities after releasing the cells.

22. The method of claim 1 , wherein cell viability is at least 98% after releasing the cells.

23. The method of claim 10 , wherein cell viability is at least 98% after releasing the cells.

24. The method of claim 20 , wherein cell viability is at least 98% after releasing the cells.

25. The method of claim 21 , wherein cell viability is at least 98% after releasing the cells.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2023
From: LIFESCAN, INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 065282/0643 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF ASSIGNEE PREVIOUSLY RECORDED AT REEL: 022457 FRAME: 0468. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 19, 2023
From: NELSON, SHELLEY
To: LIFESCAN, INC.
Reel/Frame 065290/0347 →
RELEASE OF SECOND LIEN PATENT SECURITY AGREEMENT RECORDED OCT. 3, 2018, REEL/FRAME 047186/0836 Recorded Jun 28, 2023
From: BANK OF AMERICA, N.A.
To: LIFESCAN IP HOLDINGS, LLC; JANSSEN BIOTECH, INC.; JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 064206/0176 →
CORRECTIVE RELEASE OF 1ST LIEN SECURITY INTEREST Recorded Jan 18, 2019
From: BANK OF AMERICA, N.A.
To: LIFESCAN IP HOLDINGS, LLC
Reel/Frame 049670/0224 →
CORRECTIVE RELEASE OF 2ND LIEN SECURITY INTEREST Recorded Jan 18, 2019
From: BANK OF AMERICA, N.A.
To: LIFESCAN IP HOLDINGS, LLC
Reel/Frame 049516/0487 →
SECURITY AGREEMENT Recorded Oct 3, 2018
From: LIFESCAN IP HOLDINGS, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 047186/0836 →
SECURITY AGREEMENT Recorded Oct 2, 2018
From: LIFESCAN IP HOLDINGS, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 047179/0150 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2009
From: NELSON, SHELLEY
To: LIFESCAN CORPORATION
Reel/Frame 022457/0468 →
Continuity (2)
Provisional Application 60947444 · Jul 1, 2007
Related Publication 20090325294A1 · Dec 31, 2009